X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will fund the commercial development program for AVERSA Fentanyl, which has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2024
Details:
The primary use of proceeds will be for completing the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 19, 2024
Details:
Aversa (fentanyl) abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Kindeva will perform commercial manufacturing process development and manufacture clinical supplies for Aversa Fentanyl, which combines Nutriband's AVERSA™ abuse-deterrent transdermal technology with Kindeva's FDA-approved transdermal fentanyl patch system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Kindeva Drug Delivery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2024
Details:
The net proceeds will be used to fund the development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 14, 2023
Details:
AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kindeva Drug Delivery
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
The financing will be used for commercialising AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023
Details:
Aversa (fentanyl) abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential such as opioids used to treat moderate to severe chronic pain.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Aversa (fentanyl) is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Company’s recent successful uplisting to NASDAQ and financing, has started the commercial development of AVERSA™ Fentanyl, which has the potential to be the world’s first fentanyl transdermal system with abuse deterrent properties.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
